The KRCC1 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely utilized HEK293T human cell line, in which the KRCC1 gene has been disrupted to create a loss-of-function model. This product provides a versatile platform for investigating the biological role of KRCC1, a pro-apoptotic protein implicated in mitochondrial apoptosis and protein kinase C delta (PKC-delta) signaling. As a polyclonal population, it reflects the heterogeneous editing outcomes typical of CRISPR-based gene disruption, making it suitable for functional studies where clonal variation is acceptable or where pooled analysis is desired. Researchers can employ this knockout model to dissect KRCC1-dependent processes in apoptosis, cancer biology, and mitochondrial dysfunction, without the constraint of single-cell-derived clonal artifacts.
HEK293T cells are of human embryonic kidney epithelial origin, transformed with adenovirus 5 DNA, and stably express the SV40 large T antigen. This background endows them with high transfection efficiency and robust protein expression capabilities, rendering them a standard host for a multitude of molecular and cellular biology applications. Their epithelial lineage and established use in apoptosis research make them particularly suited for studying native and stimulated cell death pathways. The combination of easy genetic manipulation and well-characterized apoptotic signaling in HEK293T cells provides a robust context in which to evaluate the functional consequences of KRCC1 disruption.
KRCC1 functions as a pro-apoptotic mediator that links protein kinase C delta (PRKCD) signaling to the intrinsic mitochondrial apoptosis machinery. Mechanistically, KRCC1 interacts with and is phosphorylated by PRKCD, which promotes its translocation to mitochondria. At the mitochondria, KRCC1 engages BAX, facilitating BAX activation and oligomerization, which leads to cytochrome c release into the cytoplasm. Released cytochrome c binds APAF1, forming the apoptosome that recruits and activates initiator caspase-9, which in turn cleaves and activates effector caspase-3. Thus, KRCC1 serves as a critical conduit downstream of PRKCD and upstream of BAX, connecting extracellular and intracellular signals to the execution phase of apoptosis. Other representative pathway components include CYCS (cytochrome c) and the caspase cascade, highlighting the gene’s central role in cell death regulation.
In the HEK293T background, knockout of KRCC1 provides a straightforward model to assess the impact of disrupted mitochondrial apoptosis signaling on cellular responses to stress. Loss of KRCC1 is expected to impair PRKCD-induced BAX activation and cytochrome c release, potentially conferring resistance to specific apoptotic stimuli. This system enables the investigation of PKC-delta-mediated apoptosis independently of other death receptor pathways and facilitates the identification of compensatory mechanisms that may arise upon KRCC1 deficiency. Moreover, these cells are well-suited for comparative studies with wild-type HEK293T cells to delineate the precise molecular events governing mitochondrial outer membrane permeabilization and subsequent caspase activation.
This polyclonal knockout cell population is designed for a range of detailed research applications, including apoptosis quantification via Annexin V flow cytometry, Western blot analysis of cleaved caspase-3 and caspase-9, and cytochrome c release assays. Additional assays such as JC-1 mitochondrial membrane potential measurement, caspase activity assays, and RT-qPCR for apoptosis markers further enable comprehensive characterization of the role of KRCC1 in cell death pathways. Researchers can leverage these cells to study cancer cell death resistance mechanisms, screen for modulators of the PRKCD?CKRCC1?CBAX signaling axis, or explore mitochondrial dysfunction in neurodegenerative disease models. For more information, please contact Ascent Research.
